Professor, Medicine, University of Florida College of Medicine
Hematology
Dr. John W. Hiemenz, MD
|
|
Give Review
John W. Hiemenz practices Hematology. He studied medicine at University of Virginia School of Medicine. John Hiemenz is also published. He has 47 publications published. The lastest publication: "Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.' He is registered with Medicare.
Publications
- Aztreonam for febrile Neutropenia in patients with beta-lactam allergy.
- How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic Cell transplantation.
- Hematopoietic stem Cell transplantation: an overview of infection risks and epidemiology.
- Management of infections complicating allogeneic hematopoietic stem Cell transplantation.
- Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.
- Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?
- New beta-lactam antibiotics in granulocytopenic patients. New options and new questions.
- Approaching the controversies in antibacterial management of Cancer patients.
- A randomized trial comparing ceftazidime alone with combination antibiotic therapy in Cancer patients with fever and neutropenia.
- A randomized trial of open lung biopsy versus empiric antimicrobial therapy in Cancer patients with diffuse pulmonary infiltrates.
- Infections due to emerging and uncommon medically important fungal pathogens.
- Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult p...
- A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during Cancer chemotherapy.
- Evolving risk factors for invasive fungal infections--all neutropenic patients are not the same.
- The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.
- Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study G...
- Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
- Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
- Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem Cell rescue for multiple myeloma.
- Population pharmacokinetics of micafungin in adult patients.
- Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem Cell transplantation.
- The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis.
- Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.
- Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.
- Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.
- Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.
- When, how, what, and where to purge are not the questions either.
- Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast Cancer patients.
- High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem Cell reinfusion.
- Invasive fusariosis associated with an injury by a stingray barb.
- Rigors with vancomycin.
- Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases.
- High-dose chemotherapy and autologous peripheral blood stem Cell transplantation in patients with multiple myeloma and renal insufficiency.
- Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem Cell transplantation.
- Nocardiosis after bone marrow transplantation: a retrospective study.
- Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
- Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple Myeloma.
- Identification of an amphotericin B resistant strain of Candida albicans using a rapid 3H-glucose incorporation microassay.
- Methylobacterium bacteremia after infusion of contaminated autologous bone marrow.
- Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem Cell transplantation for hematological malignancies: toxicitie...
- Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.
- Lipid formulations of amphotericin B: recent progress and future directions.
- Malassezia furfur folliculitis in Cancer patients. The need for interaction of microbiologist, surgical pathologist, and clinician in facilitating identification by th...
- Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation.
- Two novel high-dose treatment regimens for metastatic breast Cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
- Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Schools
University of Virginia Main Campus
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- AvMed
- Blue Card PPO
- Blue Care HMO
- BlueDental Choice
- NetworkBlue
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Employer Group PPO
- First Health (Coventry Health Care) PPO
- Medicare Advantage PFFS
- Choice Care PPO
- Select HMO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- MVP Health Care
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
National Institutes of Health Clinical Center -
University of Iowa Hospitals and Clinics -
University of Virginia School of Medicine
Hospital
-
UF Health Shands Hospital
Drug Facts
| NPI NUMBER | 1447271887 | |
| NPPES Provider LastName | HIEMENZ | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 326103003 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 365.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 24.0 | |
| Percent Opioid Claims | 6.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447271887 |
| Last Name Of The Provider | HIEMENZ |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Thomas J. George Jr., MD |
|
|
Dr. William S. May Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David F. Pawliger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Constance M. Yuan, MD |
|
Dr. Dean L. McCarley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica M. Linder, MD |
|
|
Dr. Laura S. Lourdes, MD |